IRulya Therapeutics Inc. Common Stock
IRLA
42 hedge funds and large institutions have $12M invested in IRulya Therapeutics Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 13 reducing their positions, and 8 closing their positions.
5,900% more call options, than puts
Call options by funds: $360K | Put options by funds: $6K
248% more capital invested
Capital invested by funds: $3.44M → $12M (+$8.54M)
6.22% more ownership
Funds ownership: 14.95% → 21.17% (+6.2%)
13% less funds holding
Funds holding: 48 → 42 (-6)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
62% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.54M |
| 2 |
Renaissance Technologies
New York
|
+$74K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$11.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$340K |
| 2 |
Two Sigma Investments
New York
|
-$333K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$244K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$105K |
| 5 |
ECG
EPIQ Capital Group
San Francisco,
California
|
-$95.7K |
IRLA Hedge Fund Activity: Q1 2023 in Review
42 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q1 2023, worth a combined $12M — up 248% from $3.44M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of IRLA and 4 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 5 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $3.54M. The largest seller was Millennium Management, cutting an estimated $340K.
- 42 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q1 2023, down from 48 in Q4 2022.
- Funds reported $12M of IRulya Therapeutics Inc. Common Stock stock for Q1 2023, up 248% quarter-over-quarter.
- 4 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q1 2023 and 8 closed out, a net change of -4 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q1 2023 was Tang Capital Management, an estimated $3.54M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q1 2023 was Millennium Management, an estimated $340K sold.
Based on aggregated 13F filings for Q1 2023.